Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons.

30 Oct 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

Drug delivery device companies need to rethink their strategies to remain competitive

With increasing decentralization, new cell, gene and RNAI therapies, and a growing emphasis on patient self-care, many drug delivery device companies will need to rethink their strategies in order to remain competitive.

29 Oct 2009

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Dyax reports financial results for third quarter 2009; attracts a net loss of $0.17 per share

Dyax Corp. today announced financial results for the third quarter ended September 30, 2009. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

3M launches new Rapid Detection Respiratory Syncytial Virus Test

Expanding its platform of rapid diagnostic testing, 3M today announced the introduction of the 3M™ Rapid Detection RSV Test. RSV, or respiratory syncytial virus, is a respiratory virus that infects the lungs and breathing passages and is a common cause of bronchitis and pneumonia in children under one year.

28 Oct 2009

European Patent Office to grant patent for R&D Antibodies’ immunoassays and apparatuses

Research & Diagnostic Antibodies LLC (R&D Antibodies) announced today that it has received a notification stating that the European Patent Office intends to grant a patent for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology.

28 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

Vegetable intake during pregnancy can protect unborn child against diabetes

New evidence is emerging for how important it is for pregnant women to eat good, nutritious food. Expecting mothers who eat vegetables every day seem to have children who are less likely to develop type 1 diabetes, is revealed in a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

28 Oct 2009

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

Diagnostic Hybrids, a leading developer of in vitro diagnostic fluorescent staining kits and cell culture products, announces the U.S. Food and Drug Administration (FDA) (510k) clearance of its D3 FastPointTM L-DFATM Influenza A/ Influenza B Virus Identification Kit, which allows for the identification of influenza A virus and influenza B virus from a patient’s specimen in under 30 minutes.

28 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

NIH awards The Tufts CTSI and Tufts University four supplemental grants

The Tufts Clinical and Translational Science Institute (CTSI) and Tufts University today announced they are the recipients of four supplemental grant awards from the National Institutes of Health. These new awards, totaling approximately $1.73 million, are supplements to the original Clinical and Translational Science Award (CTSA) grant, UL1 RR025752 that Tufts University received in 2008 from the National Center for Research Resources.

27 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

NCMLS organises immunology congress at Nijmegen

How do cells in our immune system recognise dangerous invaders and hazardous cells, such as cancer cells? Answers to this and similar questions are evolving rapidly. A large contributor worldwide to the field of immunology is the NCMLS, Nijmegen Centre for Molecular Life Sciences of the Radboud University Nijmegen Medical Centre. The NCMLS is organising an important scientific congress on this very topic, for which the absolute world top immunology experts are coming to Nijmegen.

27 Oct 2009

Donor testing services from LABS

LABS Inc., one of the premier transplant reference and consultative laboratories in the country, announced today that it will begin offering a full range of donor testing services to the transfusion medicine and blood services industry. LABS Inc.'s acquisition of Research and Diagnostic Laboratories in October brings its expertise to blood collection programs nationwide.

27 Oct 2009

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company’s TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

27 Oct 2009

Antibody News and Research

Further Reading

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Drug delivery device companies need to rethink their strategies to remain competitive

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Dyax reports financial results for third quarter 2009; attracts a net loss of $0.17 per share

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

3M launches new Rapid Detection Respiratory Syncytial Virus Test

European Patent Office to grant patent for R&D Antibodies’ immunoassays and apparatuses

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Recruitment of Phase II trial of TB-402 completed ahead of schedule

Vegetable intake during pregnancy can protect unborn child against diabetes

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

Starting Grant from ERC to LMU junior researchers

NIH awards The Tufts CTSI and Tufts University four supplemental grants

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

NCMLS organises immunology congress at Nijmegen

Donor testing services from LABS

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News